Andrews PL. Physiology of nausea and vomiting. Br J Anaesth 1992; 69: 2S-19S
Andrews PLR, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 1993; 32: 799-806
Apfel CC, Greim CA, Haubitz I, et al. A risk score to predict the probability of postoperative vomiting in adults. Acta Anaesthesiol Scand 1998; 42: 495-501
Apfel CC, Greim CA, Haubitz I, et al. The discriminating power of a risk score for postoperative vomiting in adults undergoing various types of surgery. Acta Anaesthesiol Scand 1998; 42: 502-9
Apfel CC, Kranke P, Katz MH, et al. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 2002; 88: 659-68
Apfel CC, Laara E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91: 693-700
Aziz Z, Arpornwirat W, Herrstedt J, et al. Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2008; 26(20 Suppl): abstr 20512
Bianchi AL, Grélot L. An overview of emesis. In: Bianchi AL, Grélot L, Miller AD, King GL, eds. New Vistas on Mechanisms and Control of Emesis, vol. 223. Colloque INSERM/John Libbey Eurotext Ltd, 1992; 3-9
Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res 1984; 11: 277-81
Chung F, Singla N, Singla S. Casopitant for preventing postoperative vomiting in patients receiving opioids: pooled data analysis. ASA Annual Meeting. 2006; A206
Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 823-5
Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative interview: assessing risk factors for nausea and vomiting. Anesth Analg 1994; 78: 7-16
Diemunsch P, Apfel C, Gan TJ, et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin 2007; 23: 2559-65
Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007; 99: 202-11
Diemunsch P, Grelot L. Potential of substance P antagonists as anti-emetics. Drugs 2000; 60: 533-46
Diemunsch P, Grélot L. Potential of substance P antagonists as antiemetics. In: Donnerer J, ed. Antiemetic Therapy. Basle: Karger, 2003; 78-97
Diemunsch P, Schoeffler P, Bryssine B, et al. Anti-emetic activity of the NK1 receptor antagonist GR205171 in the treatment of established PONV following major gynaecological surgery. Br J Anaesth 1999; 82: 274-6
Dionne RA, Max MB, Gordon SM, et al. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 1998; 64: 562-8
Dockray GJ, Green T, Varro A. The afferent peptidergic inner-vation of the upper gastrointestinal tract. In: Singer MV, Goebell H, eds. Nerves and GI Tract. Falk Symposium 50. Lancaster: Kluwer Academic, 1989; 105-22
Dockray GJ, Sharkey KA. Neurochemistry of visceral afferent neurones. Prog Brain Res 1986; 67: 133-48
Eberhart LH, Geldner G, Kranke P, et al. The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. Anesth Analg 2004; 99: 1630-7
Eberhart LH, Morin AM, Guber D, et al. Applicability of risk scores for postoperative nausea and vomiting in adults to paedia-tric patients. Br J Anaesth 2004; 93: 386-92
Fasth KJ, Bergstrom M, Kilpatrick G, et al. Brain uptake and receptor binding of two 11C-labelled selective high affinity NK1-antagonists, GR203040 and GR205171. J Label Compd Radiopharm 1997; 40: 665-7
Fukuda H, Koga T. The Bötzinger complex as the pattern generator for retching and vomiting in the dog. Neurosci Res 1991; 12: 471-85
Fumoleau P, Graham E, Giovanni M, et al. Control of acute cisplatin-induced emesis and nausea with the NK1 receptor antagonist GR205171 in combination with ondansetron. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 58a, 225
Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006; 102: 1884-98
Gan TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondanse-tron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104: 1082-9
Gan TJ, Meyer T, Apfel CC, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003; 97: 62-71
Gan TJ, Sloan F, Dear GL, et al. How much are patients willing to pay to avoid postoperative nausea and vomiting? Anesth Analg 2001; 92: 393-400
Gan TJ, Soppitt A, Maroof M, et al. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology 2002; 97: 820-6
Gesztesi Z, Scuderi PE, White PF, et al. Substance P (neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 2000; 93: 931-7
Gesztesi ZS, Song D, White PF. Comparison of a new NK1 antagonist (CP122,721) to ondansetron in the prevention of postoperative nausea and vomiting. Anesth Analg 1998; 86(Suppl 2): S32
Gold BS, Kitz DS, Lecky JH, et al. Unanticipated admission to the hospital following ambulatory surgery. J Am Med Assoc 1989; 262: 3008-10
Grélot L, Miller AD. Vomiting: its in and outs. News Physiol Sci 1994; 9: 142-6
Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2005; 13: 80-4
Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002; 63(Suppl 11): 18-24
Henry JL. Discussion of Nomenclature for TKs and Tachykin Receptor. Substance P and Neurokinins. New York: Springer-Verlag, 1987; XVII
Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2008; 19(Suppl 2): ii110-2
Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-94
Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006; 14: 354-60
Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003; 39: 1074-80
Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001; 111(Suppl 8A): 106S-12S
Janicki PK, Schuler HG, Jarzembowski TM, et al. Prevention of postoperative nausea and vomiting with granisetron and dolase-tron in relation to CYP2D6 genotype. Anesth Analg 2006; 102: 1127-33
Junger A, Hartmann B, Benson M, et al. The use of an anesthesia information management system for prediction of antiemetic rescue treatment at the postanesthesia care unit. Anesth Analg 2001; 92: 1203-9
Kerger H, Turan A, Kredel M, et al. Patients' willingness to pay for anti-emetic treatment. Acta Anaesthesiol Scand 2007; 51: 38-43
Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema to the pattern generator for the emetic act in dogs. Neurosci Res 1992; 14: 166-79
Koivuranta M, Laara E, Snare L, et al. A survey of postoperative nausea and vomiting. Anaesthesia 1997; 52 : 443-9
Kranke P, Apefel CC, Papenfuss T, et al. An increased body mass index is no risk factor for postoperative nausea and vomiting. A systematic review and results of original data. Acta Anaesthesiol Scand 2001; 45: 160-6
Kris MG, Radford JE, Pizzo BA, et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997; 89: 817-8
Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007; 47: 834-40
Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema and dorsal motor nucleus of the vagus. Neurochem Int 1985; 7: 191-211
Lim R, Morrill JM, Prushik SG, et al. An FDA approved neurokinin-1 receptor antagonist is effective in reducing intraab-dominal adhesions when administered intraperitoneally, but not orally. J Gastrointest Surg 2008; 12: 1754-61
Lucot JB. 5-HT1A receptor agonists as anti-emetic. In: Reynolds DJM, Andrew PLR, Davis CJ, eds. Serotonin and the Scientific Basis of Anti-emetic Therapy. Oxford, UK: Oxford Clinical Communications, 1995; 222-7
Macario A, Weininger M, Carney S, et al. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg 1999; 89: 652-8
Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995; 26: 911-44
Majumdar AK, Howard L, Goldberg MR, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006; 46: 291-300
McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neu-rokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74: 17-24
Minami M, Endo T, Kikuchi K, et al. Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret. Eur J Pharmacol 1998; 363: 49-55
Myles PS, Williams DL, Hendrata M, et al. Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J Anaesth 2000; 84: 6-10
Nielsen M, Olsen NV. Genetic polymorphisms in the cytochrome P450 system and efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Br J Anaesth 2008; 101: 441-5
Pierre S, Corno G, Benais H, et al. A risk score-dependent antie-metic approach effectively reduces postoperative nausea and vomiting - a continuous quality improvement initiative. Can J Anaesth 2004; 51: 320-5
Reid K, Palmer JL, Wright RJ, et al. Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 2000; 50: 61-4
Saito R, Suehiro Y, Ariumi H, et al. Anti-emetic effects of a novel NK-1 receptor antagonist HSP-117 in ferrets. Neurosci Lett 1998; 254: 169-72
Sakurada T, Sakudara C, Tan-No K, et al. Neurokinin receptor antagonists; therapeutic potential in the treatment of pain syndromes. CNS Drugs 1997; 8: 436-47
Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999; 91: 109-18
Stadler M, Bardiau F, Seidel L, et al. Difference in risk factors for postoperative nausea and vomiting. Anesthesiology 2003; 98: 46-52
Yeong-Shiuh T. Aprepitant versus multimodal antiemetic prophylaxis following extended-release epidural morphine. ASA Annual Meeting 2008; A1587